Advertisement

Editor Profile

Helmut Albrecht, MD

Associate Editor

About the NEJM Journal Watch AIDS Clinical Care Board

Helmut Albrecht, MD, is the Heyward Gibbes Distinguished Professor of Medicine and Chief of the Division of Infectious Diseases at the University of South Carolina School of Medicine. He has served as an investigator of multiple national and international trials, and has published several book chapters and more than 100 articles in peer-reviewed journals. He is a founding member and former president of KAAD (Klinische Arbeitsgemeinschaft AIDS Deutschland/German AIDS Clinical Trial Group). Dr. Albrecht has served on the NEJM Journal Watch AIDS Clinical Care Editorial Board since 2004.

Disclosures

Grant / Research support

Department of Defense; Health Resources and Services Administration; Housing Opportunities for Persons with AIDS / U.S. Department of Housing and Urban Development

Leadership positions in professional societies

Palmetto Health Richland Hospital (Chief of Staff); South Carolina Infectious Diseases Society (President)

Summaries by Helmut Albrecht

  • March 7, 2014

    Low-Dose Efavirenz — The New Standard?

    1. Helmut Albrecht, MD

    Efavirenz at 400 mg daily was as effective as — and better tolerated than — the standard 600-mg dose and would provide substantial savings.

  • January 21, 2014

    Severe Chronic Kidney Disease in HIV-Infected Patients

    1. Helmut Albrecht, MD

    Current CD4-cell count and traditional non-HIV risk factors — but not the antiretrovirals used — were the strongest predictors.

  • January 10, 2014

    Telaprevir in Acute HCV Infection

    1. Helmut Albrecht, MD

    A small pilot study showed promising efficacy and an acceptable safety profile when telaprevir was added to a standard interferon/ribavirin regimen in HIV patients with acute HCV infection.

  • October 15, 2013

    Elite HIV Controllers

    1. Helmut Albrecht, MD

    In a large group of seroconverters, 1.4% were elite controllers, and most of these individuals maintained control for longer than 20 years.

  • May 24, 2013

    Preventing HBV Infection with ART
    Free

    1. Helmut Albrecht, MD

    Antiretroviral regimens containing 3TC, tenofovir, or both, reduced the risk for incident hepatitis B virus infection by approximately 90% compared with other or no antiretrovirals.

  • May 6, 2013

    Survival Improvement with ART — Not Only for the Developed World
    Free

    1. Helmut Albrecht, MD

    ART was associated with improved survival in a large South African study, but retention in care and sustainability remain challenges to long-term success.

Pages